Dr Prash

About Dr Prash

A Founding Member of Psychedelic Institute Australia, Dr. Prash Puspanathan is a Consultant Psychiatrist in Melbourne who develops and works with novel therapeutic modalities. He is also the Co-Founder of two companies at the forefront of disruptive innovation. One of them, Enosis Therapeutics, has developed a patent-pending, novel therapeutic methodology called Spatial Therapeutics (STx), a means of remote mental health care delivery designed for Spatial Computing, to keep pace with a three-dimensional technological future.

Enosis is pioneering the academic field of the synergistic effect of Virtual Reality and Psychedelic Therapy, a concept they first introduced in 2021.

For a decade, Prash has been one of Australia's longest-standing advocates for Psychedelic-Assisted Psychotherapy. He is also one of the founding members of Psychedelic Institute Australia, providing the gold standard in the field.

Workshop Presentation: The Psychedelic Industrial Complex: Boom or Bust Psychedelics and their therapeutic use have progressed from being a spiritual and cultural construct into a scientific field, and more recently, into an industry. The mandate of stewardship has thus been unconsciously passed from science to the capital markets; from clinicians and traditional healers to CEOs, venture capitalists, and regulatory agencies.

The field has become susceptible to a range of external forces—fiscal, geopolitical, and social trends—beyond the control of those working at its coalface. Additionally, it has become permeable to cross-industry influences, such as technology, with the notable influence of artificial intelligence, pharmaceuticals, social media, and even the military-industrial complex.

This has affected the academic landscape of psychedelics, clinician attitudes and processes, and the contextual influences that shape a broader view of a patient's "setting."

This talk addresses the shifting landscape of therapeutic psychedelic use, transitioning from traditional and ritualistic settings into clinical and scientific environments, as well as the impact of big business on its future.